Clinical Characteristic of Thoracic Malignancy Patients with Coronavirus Disease 2019 Related to Mitigation Strategy in Dharmais National Cancer Center Hospital, Indonesia
DOI:
https://doi.org/10.3889/oamjms.2021.6525Keywords:
Thoracic malignancy, Coronavirus disease 2019, Disease severity, MitigationAbstract
Aim: To describe the clinical data and disease severity of thoracic malignancy patients with COVID-19 and its relation to the mitigation process at the Dharmais National Cancer Center, Indonesia.
Methods: Total 5256 cancer patients registered from May 2020 to March 2021. There were 681 cancer patients diagnosed with COVID-19. Forty-five thoracic malignancy patients were enrolled. Data from medical records were obtained at the Dharmais Cancer Hospital, then analyzed using SPSS version 25. Comparative result was considered significant, as p-value < 0.05.
Results: There were 12.9% of total patients registered infected by COVID-19, which 6% with thoracic malignancy dominated by Non-small cell lung carcinoma (57.8%). Patients who have asymptomatic (31.1%), mild (13.3%), and moderate COVID-19 disease (8.9%) were alive. Patient with severe disease (46.7%) tend to deteriorate. Neutrophilia (mean 78.0%), lymphopenia (mean 13.0%), high neutrophil to lymphocyte ratio (mean 13.1), hyperuricemia (mean 31.6 mg/dL), high fibrinogen (mean 521.7 mg/dL), and high d-dimer (mean 3821.6 ng/mL) were significantly associated with disease severity (p-value < 0.05).
Conclusions: Only small number of cancer patients affected by COVID-19 and mostly do not progress to severe disease, showing the strict mitigation strategy was successful. Severe disease patients have a poor prognosis, with neutrophilia, lymphopenia, high neutrophil to lymphocyte ratio, hyperuricemia, high fibrinogen, and high d-dimer may be valuable for predicting poor prognosis.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-207.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(6):157-60. PMid:32191675
World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Organization; 2021.
Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: A propensity score-matched analysis. J Hematol Oncol. 2020;13(1):75. https://doi.org/10.1186/s13045-020-00907-0 PMid:32522278
Rogado J, Pangua C, Serrano-Montero G, Obispo B, Marino AM, Pérez-Pérez M, et al. Covid-19 and lung cancer: A greater fatality rate? Lung Cancer. 2020;146(1):19-22. https://doi.org/10.1016/j.lungcan.2020.05.034 PMid:32505076
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: A multi-center study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783-91. https://doi.org/10.1158/2159-8290.cd-20-0422 PMid:32345594
Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;31(10):1386-96. PMid:32561401
Dai MY, Chen Z, Leng Y, Wu M, Liu Y, Zhou F, et al. Patients with lung cancer have high susceptibility of COVID-19: A retrospective study in Wuhan, China. Cancer Control. 2020;27(1):107327482096046. https://doi.org/10.1177/1073274820960467 PMid:32938231
World Health Organization. Clinical Management Clinical Management: Living Guidance COVID-19. Geneva: World Health Organization; 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. https://doi.org/10.1053/crad.2001.0896. [Last accessed on 2021 Apr 17].
KKBI. Tata Laksana. KKBI Daring. KKBI; 2016; Available from: https://www.kbbi.kemdikbud.go.id/entri/tatalaksana. [Last accessed on 2021 Apr 20].
World Health Organization. GLOBOCAN. Country-specific, Incidence Method, National Country-specific, Mortality. Vol. 858. Geneva: World Health Organization; 2020.
Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250-6.
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53(1):25-32. https://doi.org/10.1016/j.cytogfr.2020.05.003 PMid:32446778
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-47. https://doi.org/10.1002/ajh.25829 PMid:32282949
Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389-99. https://doi.org/10.1080/10408363. 2020.1770685 PMid:32503382
Gounden V, Bhatt H, Jialal I. Renal Function Tests. Treasure Island, FL: StatPearls Publishing; 2021.
George C, Minter DA. Hyperuricemia. Treasure Island, FL: StatPearls Publishing; 2021.
Liu YM, Xie J, Chen MM, Zhang X, Cheng X, Li H, et al. Kidney function indicators predict adverse outcomes of COVID-19. Med (New York, NY). 2021;2(1):38-48.e2. PMid:33043313
Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: The current evidence. United Eur Gastroenterol J. 2020;8(5):509-19. https://doi.org/10.1177/2050640620924157 PMid:32450787
Downloads
Published
How to Cite
License
Copyright (c) 2020 Arif Hanafi, Noorwati Soetandyo, Achmad Mulawarman Jayusman, Leovinna Widjaja, Fifi Dwijayanti, Priscillia Imelda (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
